Lan Yang has been named one of the world’s most...
Read MoreLan Yang has been named one of the world’s most highly cited researchers by the Institute for Scientific Information, ranking among the top 1% in her field over the past decade.
Lan Yang has been named one of the world’s most highly cited researchers by the Institute for Scientific Information, ranking among the top 1% in her field over the past decade.
Jeff Milbrandt, MD, PhD, has been awarded the inaugural WashU Medicine Dean’s Medal for Innovation and Commercialization, recognizing his transformative discoveries in neurodegeneration and his leadership in translating breakthrough science into therapies.
NEURO360 partner work led by Randall J. Bateman, MD, is advancing global Alzheimer’s prevention trials through WashU’s DIAN-TU, which is testing whether anti-amyloid antibody therapies can stop the disease before symptoms begin.
Saint Louis University’s Jenna Gorlewicz, Ph.D., has been named to the St. Louis Business Journal’s prestigious 40 Under 40 list, recognizing her leadership in engineering, research, and community impact.
A group of researchers from WashU in the McKelvey School of Engineering and the School of Medicine have created a new kind of fiber-optic device to manipulate neural activity deep in the brain. The device, called PRIME fiber, delivers multi-site, reconfigurable optical stimulation through a single, hair-thin implant.
A $3.2M NIH grant will support groundbreaking AI-driven research by WashU’s Ganesh Chand, PhD, to uncover mechanisms behind neuropsychiatric symptoms in Alzheimer’s.
NEURO360 partner, C2N Diagnostics, is set to occupy just over half of the new space in WashU’s $100 million redevelopment, leaving room …
NEURO360 partner, Avadel Pharmaceuticals, is expanding its sleep medicine pipeline with a new potential therapy, valiloxybate for treatment of narcolepsy and idiopathic …
Lan Yang has been named one of the world’s most...
Read More
Jeff Milbrandt, MD, PhD, has been awarded the inaugural WashU...
Read More
NEURO360 partner work led by Randall J. Bateman, MD, is...
Read More
Saint Louis University’s Jenna Gorlewicz, Ph.D., has been named to...
Read More
A group of researchers from WashU in the McKelvey School...
Read More
A $3.2M NIH grant will support groundbreaking AI-driven research by...
Read More
NEURO360 partner, C2N Diagnostics, is set to occupy just over...
Read More
NEURO360 partner, Avadel Pharmaceuticals, is expanding its sleep medicine pipeline...
Read More
NEURO360, BioSTL’s NSF Engines grant application with WashU, faced delays...
Read More
Lan Yang has been named one of the world’s most highly cited researchers by the Institute for Scientific Information, ranking among the top 1% in her field over the past decade.
Jeff Milbrandt, MD, PhD, has been awarded the inaugural WashU Medicine Dean’s Medal for Innovation and Commercialization, recognizing his transformative discoveries in neurodegeneration and his leadership in translating breakthrough science into therapies.
NEURO360 partner work led by Randall J. Bateman, MD, is advancing global Alzheimer’s prevention trials through WashU’s DIAN-TU, which is testing whether anti-amyloid antibody therapies can stop the disease before symptoms begin.
Saint Louis University’s Jenna Gorlewicz, Ph.D., has been named to the St. Louis Business Journal’s prestigious 40 Under 40 list, recognizing her leadership in engineering, research, and community impact.
A group of researchers from WashU in the McKelvey School of Engineering and the School of Medicine have created a new kind of fiber-optic device to manipulate neural activity deep in the brain. The device, called PRIME fiber, delivers multi-site, reconfigurable optical stimulation through a single, hair-thin implant.
A $3.2M NIH grant will support groundbreaking AI-driven research by WashU’s Ganesh Chand, PhD, to uncover mechanisms behind neuropsychiatric symptoms in Alzheimer’s.
NEURO360 partner, C2N Diagnostics, is set to occupy just over …
NEURO360 partner, Avadel Pharmaceuticals, is expanding its sleep medicine pipeline …
NEURO360, BioSTL’s NSF Engines grant application with WashU, faced delays due to federal funding shifts—but we’re back on track. Our commitment to making St. Louis a leader in neuroscience innovation remains strong, regardless of the NSF outcome.
Women We Admire recently released their Top 50 Women Chief …
NEURO360, BioSTL’s NSF Engines grant application with WashU, faced delays due to federal funding shifts—but we’re back on track. Our commitment to making St. Louis a leader in neuroscience innovation remains strong, regardless of the NSF outcome.
NEURO360, BioSTL’s NSF Engines grant application with WashU, faced delays due to federal funding shifts—but we’re back on track. Our commitment to making St. Louis a leader in neuroscience innovation remains strong, regardless of the NSF outcome.